New late-breaking data at EAACI showed Dupixent outperformed Xolair across all primary and secondary efficacy endpoints of CRSwNP and in all asthma-rel...
diaMentis, a company developing an innovative diagnostic support technology in mental health, recognized by the U.S. Food and Drug Administration (FDA) a...
If Approved, NUMELVI Will Be the First and Only Second-Generation Janus Kinase (JAK) Inhibitor for the Treatment of Pruritus Associated with Allergic D...
Collaboration will leverage Key2Brain’s technology to develop blood-brain barrier-crossing enzyme replacement therapies for lysosomal storage disor...
Investment supports the development of first-in-class, non-addictive, non-hallucinogenic molecules with a non-synaptic target, differentiated from existi...
Faster delivery and productivity gains available thanks to expanded manufacturing capacity in chromatography resins, filtration, single-use bag...
HepaRegeniX GmbH (“HepaRegeniX”), a clinical-stage company advancing novel therapies to treat acute and chronic liver disease, announced that...
XL-protein GmbH, a pioneer in the area of biopolymers for pharmacokinetic optimization, announced that it has entered into a worldwide License, Dev...
SynaptixBio, the only company licensed to commercialise a treatment for a rare, deadly disease, says the drug could halt disease progression and even rever...
Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule all...
Sanofi is shipping Beyfortus (nirsevimab) starting in early Q3 to ensure broad availability well ahead of the 2025-2026 respiratory syncytial virus (RSV)...
Now approved in the EU, Duvyzat offers an important treatment option for delaying Duchenne muscular dystrophy (DMD) disease progression Duvyzat is an ...
Atopic dermatitis is a chronic disease that disproportionately impacts communities of color Dupixent achieved 75% or greater improvement in overall dise...
Valneva SE , a specialty vaccine company, announced positive six-month antibody persistence and safety data for its Phase 2 clinical trial evaluatin...
© 2025 Biopharma Boardroom. All Rights Reserved.
